Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060016 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
A Phase 2 study of Relapsed/Refractory Small Cell Lung Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
- 20
- Study locations
NCT05060016: Active Phase 2 study of Relapsed/Refractory Small Cell Lung Cancer, sponsored by Amgen.
NCT05060016 is a Phase 2 study of Relapsed/Refractory Small Cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 222 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05060016, a Phase 2 study of Relapsed/Refractory Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2 * evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3
Conditions Studied
Interventions
- DRUG Tarlatamab
Study Locations (20)
Other
- Universitaetsklinikum Krems - Krems
- Landeskrankenhaus Salzburg - Salzburg
- Universitair Ziekenhuis Gent - Ghent
- Grand Hopital de Charleroi - Site Saint Joseph - Gilly
North Carolina
- Duke University Medical Center - Durham
- Wake Forest Baptist Comprehensive Cancer Research Center - Winston-Salem
Ohio
- Oncology Hematology Care Inc - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Delaware
- Christiana Care Health Services - Newark
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
What the registry record for NCT05060016 still lists
NCT05060016 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Relapsed/Refractory Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.
NCT05060016 names 20 study sites across 15 states, led by Other, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05060016 about?
NCT05060016 is a clinical study titled "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)". The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) p...
What is the current status of trial NCT05060016?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2021-12-01. Estimated completion is 2027-12-30.
What conditions does trial NCT05060016 study?
This clinical trial studies the following conditions: Relapsed/Refractory Small Cell Lung Cancer.
What interventions are being tested in trial NCT05060016?
The interventions under investigation include: Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT05060016?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05060016 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05060016's enrollment target sits among peer trials
222 274th of 2000 higher than 1,726 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI